Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Value of α-methylacyl-CoA racemase immunochemistry for predicting neoplastic progression in Barrett's oesophagus.

Kastelein F, Biermann K, Steyerberg EW, Verheij J, Kalisvaart M, Looijenga LH, Stoop HA, Walter L, Kuipers EJ, Spaander MC, Bruno MJ; ProBar study group..

Histopathology. 2013 Nov;63(5):630-9. doi: 10.1111/his.12216.

PMID:
24004067
2.

Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.

Kastelein F, Biermann K, Steyerberg EW, Verheij J, Kalisvaart M, Looijenga LH, Stoop HA, Walter L, Kuipers EJ, Spaander MC, Bruno MJ; ProBar-study group..

Gut. 2013 Dec;62(12):1676-83. doi: 10.1136/gutjnl-2012-303594.

PMID:
23256952
3.

A study of indefinite for dysplasia in Barrett's oesophagus: reproducibility of diagnosis, clinical outcomes and predicting progression with AMACR (alpha-methylacyl-CoA-racemase).

Sonwalkar SA, Rotimi O, Scott N, Verghese E, Dixon M, Axon AT, Everett SM.

Histopathology. 2010 Jun;56(7):900-7. doi: 10.1111/j.1365-2559.2010.03571.x.

PMID:
20636793
4.

Expression of alpha-methylacyl coenzyme A racemase in the dysplasia carcinoma sequence associated with Barrett's esophagus.

Scheil-Bertram S, Lorenz D, Ell C, Sheremet E, Fisseler-Eckhoff A.

Mod Pathol. 2008 Aug;21(8):961-7. doi: 10.1038/modpathol.2008.73.

6.

Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.

Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, van Dekken H, Siersema PD, Kuipers EJ.

Am J Gastroenterol. 2009 Nov;104(11):2673-80. doi: 10.1038/ajg.2009.437.

PMID:
19638963
7.

Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.

Goodarzi M, Correa AM, Ajani JA, Swisher SG, Hofstetter WL, Guha S, Deavers MT, Rashid A, Maru DM.

Mod Pathol. 2009 Dec;22(12):1612-21. doi: 10.1038/modpathol.2009.133.

9.

Expression of alpha-methylacyl-coenzyme A racemase in dysplastic Barrett's epithelium.

Lisovsky M, Falkowski O, Bhuiya T.

Hum Pathol. 2006 Dec;37(12):1601-6.

PMID:
16996568
10.

Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression.

Kastelein F, van Olphen SH, Steyerberg EW, Spaander MC, Bruno MJ; ProBar-Study Group..

Gut. 2016 Apr;65(4):548-54. doi: 10.1136/gutjnl-2014-308802.

PMID:
25903690
12.

p16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus.

Shi XY, Bhagwandeen B, Leong AS.

Appl Immunohistochem Mol Morphol. 2008 Oct;16(5):447-52. doi: 10.1097/PAI.0b013e318168598b.

PMID:
18665038
13.

SOX2 as a novel marker to predict neoplastic progression in Barrett's esophagus.

van Olphen S, Biermann K, Spaander MC, Kastelein F, Steyerberg EW, Stoop HA, Bruno MJ, Looijenga LH.

Am J Gastroenterol. 2015 Oct;110(10):1420-8. doi: 10.1038/ajg.2015.260.

PMID:
26323187
14.

Activation of Wnt signalling promotes development of dysplasia in Barrett's oesophagus.

Moyes LH, McEwan H, Radulescu S, Pawlikowski J, Lamm CG, Nixon C, Sansom OJ, Going JJ, Fullarton GM, Adams PD.

J Pathol. 2012 Sep;228(1):99-112. doi: 10.1002/path.4058.

PMID:
22653845
15.

Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.

Lomo LC, Blount PL, Sanchez CA, Li X, Galipeau PC, Cowan DS, Ayub K, Rabinovitch PS, Reid BJ, Odze RD.

Am J Surg Pathol. 2006 Apr;30(4):423-35.

PMID:
16625087
16.

A cross sectional study of p504s, CD133, and Twist expression in the esophageal metaplasia dysplasia adenocarcinoma sequence.

Ahmad J, Arthur K, Maxwell P, Kennedy A, Johnston BT, Murray L, McManus DT.

Dis Esophagus. 2015 Apr;28(3):276-82. doi: 10.1111/dote.12181.

PMID:
24612412
17.

Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.

Kazeminezhad B, Mirafsharieh SA, Dinyari K, Azizi D, Ebrahimi A.

Turk J Gastroenterol. 2014 Jun;25(3):253-6. doi: 10.5152/tjg.2014.5454.

18.

Diagnosis and grading of dysplasia in Barrett's oesophagus.

Odze RD.

J Clin Pathol. 2006 Oct;59(10):1029-38. Review.

19.

Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel.

Duits LC, Phoa KN, Curvers WL, Ten Kate FJ, Meijer GA, Seldenrijk CA, Offerhaus GJ, Visser M, Meijer SL, Krishnadath KK, Tijssen JG, Mallant-Hent RC, Bergman JJ.

Gut. 2015 May;64(5):700-6. doi: 10.1136/gutjnl-2014-307278.

PMID:
25034523
20.

Neoplastic precursor lesions in Barrett's esophagus.

Hornick JL, Odze RD.

Gastroenterol Clin North Am. 2007 Dec;36(4):775-96, v. Review.

PMID:
17996790
Items per page

Supplemental Content

Support Center